Karyopharm Therapeutics (KPTI) Proxy Filing summary

Executive summary

• Special meeting scheduled for February 18, 2026, to be held virtually, focusing on two key proposals.

• Main agenda is to increase authorized capital stock and common stock to support future financing and strategic initiatives.

• Board recommends voting in favor of both proposals to ensure flexibility for capital raising and corporate actions.

• Forward-looking statements highlight risks and uncertainties, especially regarding future operations and capital needs.

Voting matters and shareholder proposals

• Proposal 1 seeks to amend the Restated Certificate of Incorporation to increase authorized capital stock from 58,333,333 to 111,000,000 and common stock from 53,333,333 to 106,000,000.

• Proposal 2 allows adjournment of the meeting if more time is needed to solicit votes for Proposal 1.

• Board recommends voting FOR both proposals.

• Only stockholders of record as of December 29, 2025, are eligible to vote.

• Stockholder proposals for the 2026 annual meeting must be received by December 15, 2025, for inclusion.

Board of directors and corporate governance

• Board retains discretion to abandon the authorized shares amendment if deemed not in the best interest of the company or stockholders.

• No other business will be transacted at the special meeting beyond the stated proposals.